

REMARKS

Claims 1-37 were pending in the subject application. By this Amendment, Claims 20-23 and 34 have been canceled without prejudice or disclaimer. The presently canceled claims represent subject matter that is not being elected for prosecution in reply to the restriction requirement discussed below. Upon entry of the amendment, Claims 1-19, 24-33 and 35-37 will be pending and under examination.

The specification has been amended to clarify and conform the description to the subject matter elected for prosecution.

Applicants maintain that the amendments do not raise an issue of new matter. Accordingly, entry of the amendments is respectfully requested.

Restriction Requirement

Restriction to one of the following two Groups of inventions is required under 35 U.S.C. §121:

- I. Claims 1-19, 24-33 and 35-37 as specifically drawn to a method of treating and/or imaging a tumor in a subject comprising administering an amount of a radiolabeled antibody effect to treat and/or image said tumor.
- II. Claims 5, 7-11, 15-16, 20-23, 25 and 37 as specifically drawn to a method of imaging a tumor in a subject comprising administering an amount of a radiolabeled peptide effect to image said tumor.

In reply, applicants herewith elect to prosecute the invention identified by the Examiner as Group I, i.e. claims directed to methods of treating and/or imaging a tumor in a subject comprising administering an amount of a radiolabeled antibody effect to treat and/or image said tumor.

Applicants: Ekaterina Dadachova et al.
Appl. No.: 10/775,869
Filed: February 10, 2004
Page 9 of 9

Applicants have hereinabove amended the application to cancel claims directed to non-elected subject matter.

Information Disclosure Statement

In accordance with the duty of disclosure, applicants would like to direct the Examiner's attention to U.S. Patent Application No. 11/201,394, filed on August 10, 2005, which is a continuation-in-part of the subject application and which has claims directed to treating and imaging tumors using radiolabeled peptides.

CONCLUSIONS


No fee is deemed necessary in connection with the filing of this reply. However, if any fee is required to preserve the pendency of the subject application, authorization is hereby given to charge the amount of any such fee to Deposit Account No. 01-1785.

Respectfully submitted,

AMSTER, ROTHSTEIN & EBENSTEIN LLP
Attorneys for Applicants
90 Park Avenue
New York, New York 10016
(212) 336-8000

Dated: New York, New York
December 8, 2005

By:



Alan D. Miller
Registration No: 42,889